§ Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus.
§ The members of this class include Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin and Alogliptin.
§ DPP4 inhibitors help to increase the postprandial insulin secretion and inhibit glucagon secretion through the inhibition of inactivation of Glucagon-like peptide 1 (GLP 1) and Glucose-dependent insulinotropic polypeptide (GIP).
§ Clinically Significant interactions of Saxagliptin include
Ø Ketoconazole
Ø Diltiazem
§ No clinically significant drug interactions have been reported with the use ofvarious DPP4 inhibitors and drugs like warfarin, digoxin or cyclosporine.
§ Healthcare professionals through the screening, education, and follow up on suspected drug interactions could reduce the risk of adverse effects.
§ The diabetic patients should always consult their physician and pharmacist before taking any new medication.
§ The diabetic patients should bring a list of all of the drugs they are taking (or simply bring the drugs themselves), including prescription drugs, over-the-counter drugs, and any supplements, herbal or otherwise, during their visit to the doctor or pharmacist.
§ The diabetic patients are encouraged to ask their doctor or pharmacist to look over their list for any potentially dangerous combinations.
§ It is recommended that people fill all their prescriptions at one pharmacy, if possible.
